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Introduction: Ocular lymphomas account for five to 10 percent of all extra-nodal lymphomas. Primary uveal
lymphoma is quite a rare entity and usually unilateral. We present a case of a primary uveal lymphoma with
conjunctival and orbital extension, successfully managed with oral chlorambucil.
Case presentation: A 71-year-old Caucasian man presented to our facility with visual loss in his only functioning
eye (left). On clinical examination, we found a conjunctival lesion with a choroidal infiltration and a secondary
retinal detachment. Ultrasound and magnetic resonance imaging studies revealed a choroidal tumour mass and
two other lesions around the optic nerve. Results from an incisional biopsy revealed a low-grade B-cell lymphoma
(CD20+, CD43+, bcl2+, CD3-). A diagnosis of primary uveal lymphoma was made. Our patient was started on a
chemotherapy regime with no effect, and then oral chlorambucil was administered, with a relatively good result.
At 10 months after the start of chlorambucil treatment, a best-corrected visual acuity of 0.4 was recorded, the
choroidal mass had practically disappeared and the extra-ocular lesions had shrunk.
Conclusions: In all, 61 to 80 cases of primary uveal lymphoma have already been described in the literature.
Generally, it is an indolent tumor with a good prognosis. However, there are some reports of aggressive tumor
behavior a few years after initial diagnosis (about eight percent of cases). Other treatment options are orbital
irradiation at low doses (20 to 40 Gy) or steroid administration. This is the first documented report of the efficacy of
oral chlorambucil in the treatment of primary uveal lymphoma.
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Ophthalmic lymphomas account for five to 10 percent
of all extra-nodal lymphomas [1,2]. The majority of
orbital or conjunctival lymphomas are mucosa-associated
lymphoid tissue (MALT) lymphomas. Primary uveal
lymphoma “(‘infiltration lymphoïde uvéal’ [ILU])” is quite
a rare entity, and is generally unilateral. In contrast,
primary vitreoretinal lymphoma may be bilateral and
very aggressive, with the prompt invasion of the central
nervous system (CNS).
Here, we present a case of a primary uveal lymphoma
with typical conjunctival and orbital extension successfully
managed with oral chlorambucil.* Correspondence: iwona.rospond-kubiak@wp.pl
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A 71-year-old Caucasian man was referred to our facility
due to sudden visual deterioration in his only functional
eye (left). His vision was 0.2 in the affected eye and hand
movement only with the right eye, which had been
amblyopic since his childhood.
Anterior segment biomicroscopy results revealed a left
conjunctival lesion in the superotemporal quadrant. On
fundoscopy we noted a choroidal infiltration with exudative
retinal detachment (Figure 1A,B,D,F).
Ocular and orbital imaging results revealed a choroidal
mass (thickening of chorioretinal layer extending for
2.5mm) and two retrobulbar lesions around the optic
nerve (6.6×4.4mm and 5.8×3.3mm) (Figure 1C,D).
Incisional conjunctival biopsy results revealed a B-cell
lymphoma (CD20+, CD43+, bcl2+, CD3-). Additional
examinations (blood films, computed tomography (CT)
scans of the abdomen and thorax, and bone marrow
biopsy) excluded other systemic locations of disease.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Left eye at presentation. (A) Conjunctival lesion in the superotemporal quadrant, (B) fundus of the left eye showing the posterior pole
(B) and choroidal infiltration with secondary retinal detachment in the inferior (D) and superior (F) periphery. (C,E) Magnetic resonance imaging of the
orbits revealing left choroidal tumor mass and two lesions around the optic nerve in T1-weighted and T2-weighted images, respectively.
Figure 2 The response to oral chlorambucil at four (A,B,C) and 10 (D,E,F) months after the onset of therapy. The conjunctival lesion is
diminished (A,D), with flattening of the choroid together with disappearance of secondary retinal detachment (B,E) and regression of the
choroid mass and retrobulbar lesions on ultrasound (C,F).
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temic extension of the lymphoma, we made a final diagnosis
of a primary uveal lymphoma, which is generally an indolent
tumor with a good life prognosis.
Our patient was referred for hemato-oncologic counseling
and was initially treated with a systemic chemotherapy re-
gime (CHOP, for ‘cyclophosphamide, hydroxydaunorubicin,
Oncovin® (vincristine), prednisone’) with no effect; oral
chlorambucil was then administered, with a good response
(Figure 2).
At 10 months after the onset of chlorambucil therapy,
the best-corrected visual acuity in his left eye had improved
to 0.4, the choroidal mass had practically disappeared
and the retrobulbar lesions had regressed. At 12-month
follow-up no systemic extension was noted.Discussion
Primary uveal lymphoma is a rare pathology; there have only
been about 61 to 80 cases reported in the literature [1,2].
The first report was fromTrebenstein in 1920 [1,2].
This condition was initially considered as an inflam-
matory process rather than a proliferation of lympho-
cytes and histiocytes of low malignancy that starts in
the choroidal tissue, as it is recognized as nowadays.
Conjunctival or orbital involvement in these cases is
secondary [2]. However, recently a report of secondary
uveal infiltration by a MALT lymphoma originating
from the conjunctiva has been published [3].
Differentiating between these two types of lymphoma
can be sometimes difficult since the immunohistochemical
or histopathological characteristics of intra-ocular and
extra-ocular lesions can differ in the same patient. This
limits the reliability of excisional biopsy results [2].
Diagnosis of primary uveal lymphoma should be made
after a histopathological examination of a lesion sample in
the absence of other systemic locations of lymphoma at
presentation, as was done in our patient’s case [1].
ILU is generally believed to be an indolent tumor with
a good life expectancy. However, it can become aggressive
and some systemic extension can appear a couple of years
after initial diagnosis (this occurs in about eight percent
of cases) [3]. Other treatment options proposed in the
literature include orbital irradiation (20 to 40 Gy) or
steroids [1]. In our patient’s case, his only functional
eye was affected and there was a risk of subsequent
radiation side effects, since the tumor was covering
most of the choroid.
Chlorambucil (Leukeran®) is a nitrogen mustard al-
kylating agent mainly used in chronic lymphocytic
leukemia [4]. Its use in other systemic indolent lymphoma
is widely known, especially in older patients; with regard to
primary uveal lymphoma this is the first documented
report of its efficacy.Conclusions
In summary, to the best of our knowledge this is the first
documented report of efficacy of oral chlorambucil in
treatment of a case of ILU.
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